Centessa Pharmaceuticals Announces Addition of Patrick Yue, MD, as Senior Vice President of Clinical Development, Innovative Medicines
02 March 2023 - 12:00AM
Centessa Pharmaceuticals plc (Nasdaq: CNTA), a clinical-stage
pharmaceutical company that aims to discover and develop medicines
that are transformational for patients, today announced the
appointment of Patrick Yue, MD, to Centessa’s management team as
Senior Vice President of Clinical Development, Innovative
Medicines.
“This is an exciting time for Centessa as we are focused on the
next set of clinical milestones, including executing the pivotal
program for our lead product candidate, SerpinPC for hemophilia,
initiating the Phase 1/2a clinical studies for LB101, our first
LockBody® candidate for solid tumors, and progressing MGX292 for
PAH and our orexin agonist for narcolepsy,” said Saurabh Saha MD
PhD, Chief Executive Officer of Centessa. “Patrick is a
physician-scientist who brings extensive clinical development
experience to this newly created position at Centessa. He will
complement the outstanding team we already have in place as we
continue to advance a pipeline of medicines with the potential to
improve the lives of patients with unmet medical needs.”
“I am thrilled to join Centessa and lead clinical development
for innovative medicines alongside a team of extraordinary drug
developers,” said Dr. Yue. “I look forward to contributing as the
Company advances SerpinPC into late-stage clinical development and
progresses a compelling pipeline for the benefit of patients.”
In this newly created role, Dr. Yue will primarily focus on
select pipeline programs, including SerpinPC, MGX292 and orexin
agonists.
Prior to joining Centessa, Dr. Yue was Vice President of
Clinical Science at Global Blood Therapeutics, where he oversaw
four development programs, including voxelotor (Oxbryta) a
treatment for sickle cell disease. Dr. Yue has spent 12 years
in the biotech/pharmaceutical industry, taking on roles of
increasing responsibility at Gilead, Portola, Alexion and
Pfizer. Prior to joining the industry, Dr. Yue completed his
medical internship and residency at Beth Israel Deaconess Medical
Center and received specialty training in cardiovascular medicine
at Stanford University School of Medicine. Dr. Yue holds a BS in
Biology and Chemistry from the California Institute of Technology
(Caltech) and an MD from the Washington University School of
Medicine.
About Centessa PharmaceuticalsCentessa
Pharmaceuticals plc is a clinical-stage pharmaceutical company that
aims to discover and develop medicines that are transformational
for patients. Our programs span discovery-stage to late-stage
development and cover a range of high-value indications. We operate
with the conviction that each one of our programs has the potential
to change the current treatment paradigm and establish a new
standard of care. For more information,
visit http://www.centessa.com/, which does not form part of
this release.
Forward Looking StatementsThis press release
contains forward-looking statements. These statements may be
identified by words such as “may,” “might,” “will,” “could,”
“would,” “should,” “expect,” “intend,” “plan,” “objective,”
“anticipate,” “believe,” “estimate,” “predict,” “potential,”
“continue,” “ongoing,” “aim,” “seek,” and variations of these words
or similar expressions that are intended to identify
forward-looking statements. Any such statements in this press
release that are not statements of historical fact may be deemed to
be forward-looking statements, including statements related to the
Company’s ability to discover and develop transformational
medicines for patients; the timing of commencement of new studies
or clinical trials of SerpinPC, LB101, the LockBody technology and
other potential LockBody candidates, MGX292 and orexin agonists;
research and clinical development plans and the timing thereof; the
Company’s ability to differentiate SerpinPC, LB101, the LockBody
technology and/or other potential LockBody candidates, MGX292 and
orexin agonists from other treatment options; the development and
therapeutic potential of SerpinPC, LB101, the LockBody technology
and other potential LockBody candidates, MGX292 and orexin
agonists; and regulatory matters, including the timing and
likelihood of success of obtaining authorizations to initiate or
continue clinical trials. Any forward-looking statements in this
press release are based on our current expectations, estimates and
projections only as of the date of this release and are subject to
a number of risks and uncertainties that could cause actual results
to differ materially and adversely from those set forth in or
implied by such forward-looking statements. These risks and
uncertainties include, but are not limited to, risks related to the
safety and tolerability profile of our product candidates; our
ability to protect and maintain our intellectual property position;
business (including commercial viability), regulatory, economic and
competitive risks, uncertainties, contingencies and assumptions
about the Company; risks inherent in developing product candidates
and technologies; future results from our ongoing and planned
clinical trials; our ability to obtain adequate financing,
including through our financing facility with Oberland, to fund our
planned clinical trials and other expenses; trends in the industry;
the legal and regulatory framework for the industry, including the
receipt and maintenance of clearances to conduct or continue
clinical testing; future expenditures risks related to our
asset-centric corporate model; the risk that any one or more of our
product candidates will not be successfully developed and/or
commercialized; the risk that the results of preclinical studies or
clinical studies will not be predictive of future results in
connection with future studies; geo-political risks such as the
Russia-Ukraine war and risks related to the ongoing COVID-19
pandemic including the effects of the Delta, Omicron and any other
variants. These and other risks concerning our programs and
operations are described in additional detail in our Annual Report
on Form 10-K, Quarterly Reports on Form 10-Q, and our other
reports, which are on file with the U.S. Securities and Exchange
Commission (SEC). We explicitly disclaim any obligation to update
any forward-looking statements except to the extent required by
law.
Contact:Kristen K. Sheppard,
Esq.SVP of Investor
Relationsinvestors@centessa.com
Centessa Pharmaceuticals (NASDAQ:CNTA)
Historical Stock Chart
From Jul 2024 to Aug 2024
Centessa Pharmaceuticals (NASDAQ:CNTA)
Historical Stock Chart
From Aug 2023 to Aug 2024